Senate Investigation: Flovent Discontinuation Profited GSK, Harmed Kids
Pulling Flovent from the market in 2024 resulted in GSK profits and harm to pediatric asthma patients, according to a US Senate investigation reported by CNN.
Pulling Flovent from the market in 2024 resulted in GSK profits and harm to pediatric asthma patients, according to a US Senate investigation reported by CNN.
Pulling Flovent from the market in 2024 resulted in GSK profits and harm to pediatric asthma patients, according to a US Senate investigation reported by CNN.
Read MoreStudy suggests the 2024 withdrawal of the asthma medication Flovent was linked to increases in children discontinuing inhaled steroid therapy.
Read More